Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics


Sol-Gel Technologies Ltd. (SLGL): $4.34

0.24 (+5.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SLGL Stock Price Chart Interactive Chart >

Price chart for SLGL

SLGL Price/Volume Stats

Current price $4.34 52-week high $14.50
Prev. close $4.10 52-week low $3.94
Day low $3.95 Volume 12,600
Day high $4.51 Avg. volume 13,785
50-day MA $5.82 Dividend yield N/A
200-day MA $7.41 Market Cap 88.49M

Sol-Gel Technologies Ltd. (SLGL) Company Bio


Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel


SLGL Latest News Stream


Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream


Loading social stream, please wait...

View Full SLGL Social Stream

Latest SLGL News From Around the Web

Below are the latest news stories about Sol-Gel Technologies Ltd that investors may wish to consider to help them evaluate SLGL as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: HTG Molecular Diagnostics (HTGM), Sol-Gel Technologies (SLGL) and Ikena Oncology (IKNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HTG Molecular Diagnostics (HTGM – Research Report), Sol-Gel Technologies (SLGL – Research Report) and Ikena Oncology (IKNA – Research Report) with bullish sentiments. HTG Molecular Diagnostics (HTGM) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $9.00. The company's shares closed last Wednesday at $3.70, close to its 52-week low of $3.20. According to TipRanks.

Catie Powers on TipRanks | December 23, 2021

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the LifeSci Partners 11 th Annual Corporate Access Event and the H.C. Wainwright BioConnect Conference, both of which will be held virtually.

Intrado Digital Media | December 22, 2021

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced today that the Food and Drug Administration (FDA) has informed the Company that it intends

Yahoo | December 21, 2021

Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL)

Ascendis Pharma A/S (NASDAQ:ASND) and Sol-Gel Technologies (NASDAQ:SLGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares Ascendis Pharma A/S and Sol-Gel Technologies net margins, return on equity [] The post Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL) appeared first on ETF Daily News .

ETF Daily News | December 3, 2021

Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) have lost 23%, as stock drops 12% this past week

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

Yahoo | November 30, 2021

Read More 'SLGL' Stories Here

SLGL Price Returns

1-mo -25.94%
3-mo -40.06%
6-mo -44.50%
1-year -63.06%
3-year -51.51%
5-year N/A
YTD -41.35%
2021 -24.41%
2020 -42.92%
2019 184.88%
2018 N/A
2017 N/A

Continue Researching SLGL

Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:

Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.397 seconds.